The DOI matches its Crossref record.
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
Abstract
In a prospective double-blind trial, we treated 194 patients with acute venous thromboembolism with heparin or low molecular weight heparin (LMWH; Fragmin). To evaluate the most important prognostic factors for bleeding, the presenting clinical features of the patients, the patients' anticoagulant responses, and the doses of the drugs were analyzed using univariate and multivariate regression analyses. No significant differences in clinical risk factors associated with bleeding were observed between heparin and LMWH. The univariate analyses ranked the parameters in the following order of importance: World Health Organization (WHO) performance status, history of bleeding tendency, cardiopulmonary resuscitation, recent trauma or surgery, leukocyte counts, platelet counts, duration of symptoms, and body surface area. Patients with WHO grade 4 had an eightfold increase in risk of bleeding as compared with WHO grade 1. Assessment of the individual contribution of each variable using multivariate regression analysis showed that the WHO performance status was the most important independent factor predicting major bleeding. A history of a bleeding tendency, recent trauma or surgery, and body surface area were also independent risk factors. The risk of bleeding was influenced by two factors related to the treatment, the patient's anticoagulant response as measured with the anti-Xa assay and the dose of the drug expressed as U/24 h/m2. An increased risk of bleeding was only observed at mean anti-Xa levels greater than 0.8 U/mL for both drugs. Significantly more major bleedings occurred in patients treated with high doses of the drugs, an observation that was independent of the concomitant anti-Xa levels. It should be considered whether choosing an appropriate initial dose adapted to the patient's body surface area and clinical risk factors can improve the efficacy to safety ratio of heparin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., & Raschke, R. (2004) · Chest · doi:10.1378/chest.126.3_suppl.188s · Cited by 971
Metadata
- Authors
- Nieuwenhuis, H., Albada, J., Banga, J., & Sixma, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1991-11-01
- Volume
- 78
- Issue
- 9
- Pages
- 2337-2343
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1527283637
- Cited by
- 226
- References
- 0
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. https://app.cochat.ai/papers/10.1182/blood.v78.9.2337.2337
- The paper
- Nieuwenhuis, H., Albada, J., Banga, J., & Sixma, J. (1991). Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. https://doi.org/10.1182/blood.v78.9.2337.2337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.